Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.
Maria-Ioanna StefanouAikaterini TheodorouKonark MalhotraDiana Aguiar de SousaMira KatanLina PalaiodimouAristeidis H KatsanosIoanna KoutroulouVaia LambadiariRobin LemmensSotirios GiannopoulosAndrei V AlexandrovGerasimos SiasosGeorgios K TsivgoulisPublished in: European stroke journal (2024)
GLP-1 and GIP/GLP-1 RAs reduce cardiovascular-risk and mortality in T2DM. While there is solid evidence that GLP-1 RAs significantly attenuate the risk of ischemic stroke in T2DM, dedicated RCTs are needed to evaluate the efficacy of novel GIP/GLP-1 RAs for primary and secondary stroke prevention.